AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion. The company now projects more than ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

AbbVie Inc. (NYSE:ABBV – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $207.42 and ...

The answer to this question lies in the sharp drop in Humira sales due to the negative impact of its biosimilars and AbbVie's effort to switch patients from it to Rinvoq and Skyrizi. Second ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...